Going against the advice of its independent experts, the FDA approved Novartis’ new blood cancer drug for patients with particularly deadly forms of multiple myeloma, looking past some serious safety issues and concerns about the drug’s supporting data.

…read more

Source: Novartis bags a surprise approval for the blood cancer-treating panobinostat


0 No comments